Q-omics provides the consensus-scored RPL26P6 profile across patient tissues and cancer cell-line models. RPL26P6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL26P6 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RPL26P6 RNA expression shows 15,919 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where RPL26P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL26P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL26P6 survival associations across molecular data types. RPL26P6 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL26P6 RNA expression–survival associations across cancer types. High RPL26P6 expression shows unfavorable associations in ACC, LUAD, KICH and OV, but favorable associations in MESO and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL26P6 RNA expression.
This table summarizes RPL26P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL26P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL26P6 shows lower tumor expression in BRCA and KICH and higher tumor expression in KIRC, KIRP, CHOL and ESCA. The KIRC box plot shows higher RPL26P6 RNA expression in tumor versus normal tissue (log2 FC = +0.481, t-test p < 0.001).
This table shows molecular features associated with RPL26P6 in patient tissues and cancer cell lines. In patient samples, RPL26P6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
